Early trial of Covid-19 vaccines by Pfizer, BioNtech promising: Scientists

The research said patients treated with the vaccine candidate produced nearly 1.8 to 2.8 fold greater levels of antibodies that could neutralise SARS-CoV-2

A Covid-19 vaccine candidate, tested by the American pharmaceutical giant Pfizer, and the German biotech firm BioNTech SE, is safe, well-tolerated, and can generate antibodies in people, according to a study.

The research, which is published in the preprint server medRxiv and is yet to be peer-reviewed, describes the preliminary clinical data for the candidate vaccine -- nucleoside-modified messenger RNA (modRNA), BNT162b1.

It said the amount of antibodies produced in participants after they received two shots of the vaccine candidate was greater than that reported in patients receiving convalescent plasma from recovered Covid-19 patients.

"I was glad to see Pfizer